Chiasma Looks Ahead To First Approval With "Revolutionary" Technology Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
Anticipating an April 15 user fee date for oral ocreotide for acromegaly, Chiasma thinks its platform technology to make peptides orally available can offer substantial opportunities for therapeutic optionality.
You may also be interested in...
FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
Office of Prescription Drug Promotion seemed to expand its focus in issuing 11 letters last year.
COVID-19 Could Drive UK OTC Rises
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Sandoz Keeps Tabs On Teva Skinny Label Ruling
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: